CIGLi001-A-2
General
iPSC Line |
|
| hPSCreg name | CIGLi001-A-2 |
| Cite as: | CIGLi001-A-2 |
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines |
CIGLi001-A-6 (VULSCi002-A-6) CIGLi001-A (RPChiPS8023G1, iPSC TBX4 WT, StemRNA™ Human iPSC 802-3G, SYNTHEGO 802-30F) LUMCi004-A-1 (LU99_AAVS1-bxb-v2) MRIi003-A-11 (AAVS-CAG-DTPA-R homozygous) MRIi003-A-9 (HK-AAVS1-CAG-FRT-stop-FRT-mKate2-hetero) MRIi003-A-6 (AAVS1-CAG-VSFP-homo) MRIi003-A-5 (AAVS1-CAG-VSFP-hetero) MRIi003-A-10 (AAVS-CAG-DTPA-R heterozygous) CIGLi001-A-1 (SYNTHEGO 802-30F MUT, iPSC TBX4 MUT) |
| Last update | 6th December 2024 |
| User feedback | |
Provider |
|
| Generator |
Vilnius University (VULSC)
Contact:
Vilnius University (VULSC) |
| Derivation country | Lithuania |
External iPSC Databases |
|
| BioSamples | SAMEA117481504 |
General iPSC Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
| Subclone of | |
iPSC Genetic Modification
| Genetic modifications not related to a disease |
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Hispanic |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | no |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing
Passes test for quality control as mentioned by supplier 802 30F datasheet.pdf The company, SYNTHEGO, that is supplying the cell line to us, mentions that quality control assessment is done and sequence validation data can be provided upon request |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA114652490 |
Ethics
Also have a look at the ethics information for the parental line
CIGLi001-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Plasmids created in this study: Addgene 223321 Addgene 223323 Addgene 223328 |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CIGLi001-A.
|
|
Reprogramming method |
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
Other |
|
| Selection criteria for clones | Constitutive GNAT family puromycin N- acetyltransferase (GENE ID: WP_335902160.1) |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Laminin |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: Stemfit
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
46XX
Passage number: 6
Karyotyping method:
Molecular karyotyping by SNP array
|
Other Genotyping (iPSC Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Login to share your feedback, experiences or results with the research community.